Four weeks of ledipasvir/sofosbuvir and ribavirin with or without pegylated interferon for chronic hepatitis C in non-cirrhotic people who inject drugs. A randomized trial

Journal of Hepatology

Volumn 68, Issue 4, 2018, Pages 840-842

  Øvrehus, Anne L H ^a   Krarup, Henrik ^b   Birkemose, Inge ^c   Holm, Dorte K ^a   Mössner, Belinda ^a   Ernst, Anja ^b   Christensen, Peer B ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b AALBORG UNIVERSITY HOSPITAL   (Denmark)

^c Treatment Center Odense   (Denmark)

Author keywords

Direct acting antivirals; Hepatitis C; Intra venous drug use; Randomized clinical trial; Treatment

Indexed keywords

LEDIPASVIR PLUS SOFOSBUVIR; PEGINTERFERON ALPHA; RIBAVIRIN; ALPHA INTERFERON; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; FLUORENE DERIVATIVE; LEDIPASVIR, SOFOSBUVIR DRUG COMBINATION; MACROGOL; PEGINTERFERON ALPHA2A; RECOMBINANT PROTEIN; URIDINE PHOSPHATE;

ADULT; CHRONIC HEPATITIS C; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; INTENTION TO TREAT ANALYSIS; LETTER; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIRUS LOAD; ANALOGS AND DERIVATIVES; MIDDLE AGED;

ADULT; ANTIVIRAL AGENTS; BENZIMIDAZOLES; FEMALE; FLUORENES; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; URIDINE MONOPHOSPHATE;

EID: 85039771864     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2017.11.031     Document Type: Letter

References (10)

1. Falade-Nwulia, O., Suarez-Cuervo, C., Nelson, D.R., Fried, M.W., Segal, J.B., Sulkowski, M.S., Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review. Ann Intern Med 166 (2017), 637–648.
2. Grebely J. We know DAAs for hepatitis C work for PWID, now what? International Network for Hepatitis in Substance Users Septemeber 9th. 2017; Jersey City, USA2017.
3. Health OW. Global health sector strategy on viral hepatitis 2016–2021, 2016.
4. Perelson, A.S., Guedj, J., Modelling hepatitis C therapy–predicting effects of treatment. Nat Rev Gastroenterol Hepatol 12 (2015), 437–445.
5. Foster, G.R., Pianko, S., Brown, A., Forton, D., Nahass, R.G., George, J., et al. Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection. Gastroenterology 149 (2015), 1462–1470.
6. Mangia, A., Individualizing treatment duration in hepatitis C virus genotype 2/3-infected patients. Liver Int 31 (2011), 36–41.
7. Feld, J.J., Ramji, A., Shafran, S.D., Willems, B., Marotta, P., Huchet, E., et al. Ledipasvir-sofosbuvir plus ribavirin in treatment-naive patients with hepatitis C virus genotype 3 infection: an open-label study. Clin Infect Dis 65 (2017), 13–19.
8. Kohli, A., Kattakuzhy, S., Sidharthan, S., Nelson, A., McLaughlin, M., Seamon, C., et al. Four-week direct-acting antiviral regimens in noncirrhotic patients with hepatitis C virus genotype 1 infection: an open-label, Nonrandomized Trial. Ann Intern Med 163 (2015), 899–907.
9. Lawitz, E., Poordad, F., Gutierrez, J.A., Wells, J.T., Landaverde, C.E., Evans, B., et al. Short-duration treatment with elbasvir/grazoprevir and sofosbuvir for hepatitis C: A randomized trial. Hepatology 65 (2017), 439–450.
10. Sulkowski, M.S., Flamm, S., Kayali, Z., Lawitz, E.J., Kwo, P., McPhee, F., et al. Short-duration treatment for chronic hepatitis C virus with daclatasvir, asunaprevir, beclabuvir and sofosbuvir (FOURward study). Liver Int 37 (2016), 836–842.